We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
FDA Approves Label Expansion of Novo Nordisk's (NVO) Saxenda
Read MoreHide Full Article
Novo Nordisk A/S ((NVO - Free Report) ) announced that the FDA has approved an updated label for Saxenda (liraglutide) injection 3 mg. The Saxenda Injection is now approved for the treatment of obesity in adolescents (12-17 years) with a body weight above 60 kg and an initial body mass index (BMI) corresponding to 30 kg/m2 or greater for adults, as an adjunct to a reduced-calorie diet and increased physical activity.
Shares of the company have increased 18.9% year to date compared with the industry’s 6.6% growth.
We note that Saxenda is already indicated in the United States for chronic weight management in adults with a BMI greater than or equal to 30 kg/m2, or 27 kg/m2 or higher with at least one weight-related comorbidity, as an adjunct to a reduced-calorie diet and increased physical activity.
We note that the approval for label expansion of Saxenda was supported by data from a phase III study, which investigated the effects of Saxendacompared to placebo for weight management in 251 adolescents (aged 12-18 years) living with obesity as an adjunct to lifestyle therapy. The primary endpoint was change from baseline in BMI Standard Deviation Score (SDS) at week 56. The data showed a significant reduction in BMI-SDS and reductions in BMI, mean body weight, as well as other weight-related endpoints versus placebo in adolescents with obesity when using Saxenda as an adjunct to lifestyle therapy.
A label expansion of the drug will lead to increased sales for the company.
We note that Novo Nordisk has a strong presence in the Diabetes care market, with one of the broadest diabetes portfolios in the industry. The company has improved its global diabetes value market share from 28.4% to 29.2% over the past 12 months, driven by an improved global insulin market share and expansion of the GLP-1 segment.
Zacks Rank & Stocks to Consider
Novo Nordisk currently carries a Zacks Rank #3 (Hold).
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
FDA Approves Label Expansion of Novo Nordisk's (NVO) Saxenda
Novo Nordisk A/S ((NVO - Free Report) ) announced that the FDA has approved an updated label for Saxenda (liraglutide) injection 3 mg. The Saxenda Injection is now approved for the treatment of obesity in adolescents (12-17 years) with a body weight above 60 kg and an initial body mass index (BMI) corresponding to 30 kg/m2 or greater for adults, as an adjunct to a reduced-calorie diet and increased physical activity.
Shares of the company have increased 18.9% year to date compared with the industry’s 6.6% growth.
We note that Saxenda is already indicated in the United States for chronic weight management in adults with a BMI greater than or equal to 30 kg/m2, or 27 kg/m2 or higher with at least one weight-related comorbidity, as an adjunct to a reduced-calorie diet and increased physical activity.
We note that the approval for label expansion of Saxenda was supported by data from a phase III study, which investigated the effects of Saxendacompared to placebo for weight management in 251 adolescents (aged 12-18 years) living with obesity as an adjunct to lifestyle therapy. The primary endpoint was change from baseline in BMI Standard Deviation Score (SDS) at week 56. The data showed a significant reduction in BMI-SDS and reductions in BMI, mean body weight, as well as other weight-related endpoints versus placebo in adolescents with obesity when using Saxenda as an adjunct to lifestyle therapy.
A label expansion of the drug will lead to increased sales for the company.
We note that Novo Nordisk has a strong presence in the Diabetes care market, with one of the broadest diabetes portfolios in the industry. The company has improved its global diabetes value market share from 28.4% to 29.2% over the past 12 months, driven by an improved global insulin market share and expansion of the GLP-1 segment.
Zacks Rank & Stocks to Consider
Novo Nordisk currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the healthcare sector include Aerpio Pharmaceuticals Ltd. , Aptose Biosciences Inc. (APTO - Free Report) and Alimera Sciences Inc. , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Aerpio’s loss per share estimates have narrowed from 15 cents to 14 cents for 2020 and from 63 cents to 57 cents for 2021 over the past 60 days.
Aptose’s loss per share estimates have narrowed from 77 cents to 69 cents for 2020 and from 85 cents to 81 cents for 2021 over the past 60 days.
Alimera’s loss per share estimates have narrowed from $1.31 to 96 cents for 2020 over the past 60 days.
Novo Nordisk AS Price
Novo Nordisk AS price | Novo Nordisk AS Quote
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>